玻璃体内注射阿布西普治疗继发于增殖性糖尿病视网膜病变的虹膜红斑。

眼科学报 Pub Date : 2016-04-19 DOI:10.21037/JES.2016.04.16

Shao-Wei Weng, Tzu-Lun Huang, P. Su, P. Chang, Jiakui Wang

{"title":"玻璃体内注射阿布西普治疗继发于增殖性糖尿病视网膜病变的虹膜红斑。","authors":"Shao-Wei Weng, Tzu-Lun Huang, P. Su, P. Chang, Jiakui Wang","doi":"10.21037/JES.2016.04.16","DOIUrl":null,"url":null,"abstract":"The purpose of this article is to report a case with rubeosis iridis treated by intravitreal aflibercept. A 61-year-old man had iris neovascularization and scanty vitreous hemorrhage secondary to proliferative diabetic retinopathy in the right eye. Neither neovascularization of angle nor elevation of intraocular pressure was found. Single intravitreal aflibercept 2 mg injection was performed. Rubeosis iridis disappeared on the next day. Scattered retinal laser photocoagulation was added 1 week later. There was no recurrence after 3-month follow-up. Aflibercept may serve as another anti-vascular endothelial growth factor (anti-VEGF) for treating rubeosis iridis.","PeriodicalId":12096,"journal":{"name":"眼科学报","volume":"21 1","pages":"201-3"},"PeriodicalIF":0.0000,"publicationDate":"2016-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Intravitreal aflibercept for rubeosis iridis secondary to proliferative diabetic retinopathy.\",\"authors\":\"Shao-Wei Weng, Tzu-Lun Huang, P. Su, P. Chang, Jiakui Wang\",\"doi\":\"10.21037/JES.2016.04.16\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The purpose of this article is to report a case with rubeosis iridis treated by intravitreal aflibercept. A 61-year-old man had iris neovascularization and scanty vitreous hemorrhage secondary to proliferative diabetic retinopathy in the right eye. Neither neovascularization of angle nor elevation of intraocular pressure was found. Single intravitreal aflibercept 2 mg injection was performed. Rubeosis iridis disappeared on the next day. Scattered retinal laser photocoagulation was added 1 week later. There was no recurrence after 3-month follow-up. Aflibercept may serve as another anti-vascular endothelial growth factor (anti-VEGF) for treating rubeosis iridis.\",\"PeriodicalId\":12096,\"journal\":{\"name\":\"眼科学报\",\"volume\":\"21 1\",\"pages\":\"201-3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-04-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"眼科学报\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/JES.2016.04.16\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"眼科学报","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/JES.2016.04.16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

摘要

本文的目的是报告一例虹膜红肿用玻璃体腔内注射阿布西普治疗。一例61岁男性右眼继发于增殖性糖尿病视网膜病变，并发虹膜新生血管和少量玻璃体出血。未见新生血管形成，也未见眼压升高。单次玻璃体内注射阿布西普2 mg。第二天虹膜红肿消失。1周后加入分散视网膜激光光凝。随访3个月无复发。阿非利西普可能作为另一种抗血管内皮生长因子(anti-VEGF)治疗虹膜纤维化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Intravitreal aflibercept for rubeosis iridis secondary to proliferative diabetic retinopathy.

The purpose of this article is to report a case with rubeosis iridis treated by intravitreal aflibercept. A 61-year-old man had iris neovascularization and scanty vitreous hemorrhage secondary to proliferative diabetic retinopathy in the right eye. Neither neovascularization of angle nor elevation of intraocular pressure was found. Single intravitreal aflibercept 2 mg injection was performed. Rubeosis iridis disappeared on the next day. Scattered retinal laser photocoagulation was added 1 week later. There was no recurrence after 3-month follow-up. Aflibercept may serve as another anti-vascular endothelial growth factor (anti-VEGF) for treating rubeosis iridis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

眼科学报

自引率

0.00%

发文量

1312

期刊介绍： Eye science was founded in 1985. It is a national medical journal supervised by the Ministry of Education of the People's Republic of China, sponsored by Sun Yat-sen University, and hosted by Sun Yat-sen University Zhongshan Eye Center (in October 2020, it was changed from a quarterly to a monthly, with the publication number: ISSN: 1000-4432; CN: 44-1119/R). It is edited by Ge Jian, former dean of Sun Yat-sen University Zhongshan Eye Center, Liu Yizhi, director and dean of Sun Yat-sen University Zhongshan Eye Center, and Lin Haotian, deputy director of Sun Yat-sen University Zhongshan Eye Center, as executive editor. It mainly reports on new developments and trends in the field of ophthalmology at home and abroad, focusing on basic research in ophthalmology, clinical experience, and theoretical knowledge and technical operations related to epidemiology. It has been included in important databases at home and abroad, such as Chemical Abstract (CA), China Journal Full-text Database (CNKI), China Core Journals (Selection) Database (Wanfang), and Chinese Science and Technology Journal Database (VIP).